Hikma Pharmaceuticals PLC (HKMPY) Fair Value & Analysis
Healthcare · US · Market cap $4.1B
Hikma Pharmaceuticals PLC
HKMPY · US
Fair value as of: Jul 16, 2026
From 26 valuation models · updated 7 days ago
Share price +5.6% over the past month.
Price vs Fair Value (12 months)
12‑month range $30.99 – $54.96 · fair‑value band $28.67 – $102.32 · the $41.23 price screens below the $63.22 fair value. As of Jul 16, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Hikma Pharmaceuticals PLC (HKMPY) currently trades at $41.23, while our model-based Fair Value estimate is $63.22, implying the stock looks roughly 53.3% undervalued today. We read business quality at 52/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Hikma Pharmaceuticals PLC generated revenue of $3.3B at a net margin of 12.0%. Revenue grew 8.5% year over year. It earns a return on equity of 16.5%. Net debt stands at $1.3B. Fundamentals as of Jul 16, 2026
Our scenario range runs from $28.67 (bear case) to $102.32 (bull case); at $41.23, the current price sits within that range. The share trades about 22% below its 52-week high and 33% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at 53%, HKMPY screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 16, 2026. TTM = trailing twelve months.
About the company
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Hikma Pharmaceuticals PLC reported revenue of $3.4B in FY2025 versus $2.6B in FY2021, a compound +7.1%/yr. Reported net income was $403M in FY2025, compounding −1.1%/yr from FY2021.
Is HKMPY fairly valued? → Check now
Recent news
- Citi starts Hikma at 'buy' with strategy reset offering compelling entry point
- [Latest] Global Generic Drug Market Size/Share Worth USD 926.54 Billion by 2034 at a 6.55% CAGR: Custom Market Insights (Analysis, Outlook,
- U.S. Supreme Court Ends Amarin Patent Fight, Hikma Prevails
- Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection, not financial advice.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.01 | ¥26.59 | -43% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,464 | ₹1,504 | -66% |
| PharmaEssentia Corporation 6446 | 934.00 TWD | 365.87 TWD | -61% |
| Cipla Limited CIPLA | ₹1,416 | ₹1,466 | +4% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,112 | ₹697.22 | -37% |
| Lupin Limited LUPIN | ₹2,340 | ₹2,477 | +6% |
| Mankind Pharma Limited MANKIND | ₹2,538 | ₹1,161 | -54% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,272 | ₹720.15 | -43% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Hikma Pharmaceuticals PLC (HKMPY) undervalued?
What is the fair value of HKMPY?
What is the quality score of HKMPY?
What is the revenue of Hikma Pharmaceuticals PLC (HKMPY)?
What is the net profit margin of HKMPY?
Does Hikma Pharmaceuticals PLC pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Hikma Pharmaceuticals PLC analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.